# Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

> **NCT00283478** · NA · COMPLETED · sponsor: **Kentuckiana Cancer Institute** · enrollment: 20 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Iscar Quercus
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00283478
- **Lead sponsor:** Kentuckiana Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** —
- **Final completion:** 2007-04
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2007-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00283478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00283478, "Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00283478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*